Evidence map›Paper›PMID 29652894›Full record

ArticlePloS one2018

Piperazinyl fragment improves anticancer activity of Triapine.

Marta Rejmund, Anna Mrozek-Wilczkiewicz, Katarzyna Malarz, Monika Pyrkosz-Bulska, Kamila Gajcy, Mieczyslaw Sajewicz, Robert Musiol, Jaroslaw Polanski

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. IntegratedPharmaceuticals (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Chemistry towards Biology-Instruct: Snapshot.International journal of molecular sciences · 2022
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marta RejmundInstitute of Chemistry, University of Silesia, Katowice, Poland.
Anna Mrozek-WilczkiewiczA. Chełkowski Institute of Physics, University of Silesia, Katowice, Poland.
Katarzyna MalarzInstitute of Chemistry, University of Silesia, Katowice, Poland.
Monika Pyrkosz-BulskaInstitute of Chemistry, University of Silesia, Katowice, Poland.
Kamila GajcyInstitute of Chemistry, University of Silesia, Katowice, Poland.
Mieczyslaw SajewiczInstitute of Chemistry, University of Silesia, Katowice, Poland.
Robert MusiolInstitute of Chemistry, University of Silesia, Katowice, Poland.
Jaroslaw PolanskiInstitute of Chemistry, University of Silesia, Katowice, Poland.ORCID 0000-0003-3141-6562

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new class of TSCs containing piperazine (piperazinylogs) of Triapine, was designed to fulfill the di-substitution pattern at the TSCs N4 position, which is a crucial prerequisite for the high activity of the previously obtained TSC compounds-DpC and Dp44mT. We tested the important physicochemical characteristics of the novel compounds L1-L12. The studied ligands are neutral at physiological pH, which allows them to permeate cell membranes and bind cellular Fe pools more readily than less lipid-soluble ligands, e.g. DFO. The selectivity and anti-cancer activity of the novel TSCs were examined in a variety of cancer cell types. In general, the novel compounds demonstrated the greatest promise as anti-cancer agents with both a potent and selective anti-proliferative activity. We investigated the mechanism of action more deeply, and revealed that studied compounds inhibit the cell cycle (G1/S phase). Additionally we detected apoptosis, which is dependent on cell line's specific genetic profile. Accordingly, structure-activity relationship studies suggest that the combination of the piperazine ring with Triapine allows potent and selective anticancer chelators that warrant further in vivo examination to be identified. Significantly, this study proved the importance of the di-substitution pattern of the amine N4 function.

Indexed as

Antineoplastic AgentsApoptosisCell Line, TumorCell ProliferationCopperG1 PhaseHumansIronPiperazinePiperazinesPyridinesS PhaseStructure-Activity RelationshipThiosemicarbazones3-aminopyridine-2-carboxaldehyde thiosemicarbazoneAntineoplastic AgentsCopperIronPiperazinePiperazinesPyridinesThiosemicarbazones

Identifiers

PMID29652894
PMCPMC5898707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.